IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.50
−1.73%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.77
From 52W high−13.61%
Volume3.99M
Market cap$894.24M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$12.77
From 52W high
−13.61%
Volume
3.99M
Market cap
$894.24M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.5x
P/E (TTM)
—
RSI (14)
49.5
MomentumView details →
1D Return
−1.73%
YTD Return
+136.61%
SummaryUpdated Jun 1, 2026
Immix Biopharma, Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Los Angeles, California. The company went public in December 2021 and focuses on developing tissue-specific therapeutics for oncology and inflammatory diseases. Immix operates primarily in the United States and Australia, with its lead programs currently in various phases of clinical trials targeting cancer and inflammatory bowel diseases.
Similar companies
Latest newsMore news →
Immix Biopharma's stock reached a new 52-week high of $13.80 during mid-day trading on Tuesday, with the last trade at $13.61 and volume of 1,414,936 shares.26d agoThe Portnoy Law Firm initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors.61d ago